Table 1.
Sociodemographic and Clinical Characteristics of Male Patients Included in the Trepoli study (n = 293) by Syphilis Stage, Amsterdam, The Netherlands, November 2018 to December 2019
| Syphilis Stage | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Syphilis (n = 27) |
Primary (n = 70) |
Secondary (n = 73) |
Early Latent (n = 86) |
Late Latent (n = 14) |
Treated Syphilis (n = 23) |
|||||||
| na | %a | na | %a | na | %a | na | %a | na | %a | na | %a | |
| Demographics | ||||||||||||
| Age, y | ||||||||||||
| Median [IQR] | 35 | [27–43] | 41 | [33–50] | 39 | [33–48] | 40 | [30–52] | 35 | [26–42] | 41 | [35–48] |
| <35 y | 13 | 48% | 22 | 31% | 24 | 33% | 30 | 35% | 7 | 50% | 5 | 22% |
| 35–44 y | 8 | 30% | 21 | 30% | 25 | 34% | 21 | 24% | 6 | 43% | 9 | 39% |
| ≥45 y | 6 | 22% | 27 | 39% | 24 | 33% | 35 | 41% | 1 | 7% | 9 | 39% |
| Country of origin | ||||||||||||
| The Netherlands | 16 | 59% | 46 | 66% | 36 | 50% | 51 | 59% | 5 | 36% | 13 | 57% |
| Other | 11 | 41% | 24 | 34% | 36 | 50% | 35 | 41% | 9 | 64% | 10 | 43% |
| Education | ||||||||||||
| None/primary/secondary | 2 | 8% | 15 | 23% | 16 | 27% | 20 | 25% | 4 | 3% | 3 | 15% |
| College/university | 24 | 92% | 49 | 75% | 41 | 68% | 60 | 74% | 8 | 67% | 16 | 80% |
| Other | 0 | 0% | 1 | 2% | 3 | 5% | 1 | 1% | 0 | 0% | 1 | 5% |
| Sexual behavior | ||||||||||||
| Gender of sex partners | ||||||||||||
| Men | 26 | 96% | 68 | 97% | 73 | 100% | 85 | 99% | 13 | 93% | 22 | 96% |
| Men and women | 1 | 4% | 2 | 3% | 0 | 0% | 1 | 1% | 1 | 7% | 1 | 4% |
| No. of sexual partners (6 mo)b | ||||||||||||
| Median [IQR] | 4 | [3–15] | 8 | [4–20] | 6 | [4–15] | 10 | [5–20] | 8 | [4–12] | 8 | [5–15] |
| <5 | 14 | 52% | 19 | 27% | 23 | 32% | 16 | 20% | 5 | 36% | 5 | 22% |
| 5–9 | 4 | 15% | 18 | 26% | 18 | 25% | 21 | 26% | 2 | 14% | 7 | 30% |
| 10–14 | 2 | 7% | 11 | 16% | 11 | 15% | 14 | 18% | 4 | 29% | 3 | 13% |
| ≥15 | 7 | 26% | 22 | 31% | 21 | 29% | 29 | 36% | 3 | 21% | 8 | 35% |
| Health and biometrics | ||||||||||||
| HIV status | ||||||||||||
| Negative | 21 | 78% | 52 | 74% | 44 | 60% | 49 | 57% | 13 | 93% | 11 | 48% |
| Positive | 6 | 22% | 18 | 26% | 29 | 40% | 37 | 43% | 1 | 7% | 12 | 52% |
| cART usec | ||||||||||||
| No | 1 | 17% | 0 | 0% | 3 | 11% | 2 | 6% | 0 | 0% | 0 | 0% |
| Yes | 5 | 83% | 18 | 100% | 25 | 89% | 33 | 94% | 1 | 100% | 11 | 100% |
| Most recent CD4 count (cells/µL)c | ||||||||||||
| <350 | 0 | 0% | 0 | 0% | 1 | 5% | 0 | 0% | 0 | 0% | 0 | 0% |
| 350–499 | 0 | 0% | 0 | 0% | 2 | 10% | 1 | 3% | 0 | 0% | 0 | 0% |
| ≥500 | 4 | 100% | 14 | 100% | 17 | 85% | 29 | 97% | 1 | 100% | 8 | 100% |
| PrEP used | ||||||||||||
| No | 20 | 95% | 44 | 85% | 37 | 84% | 42 | 86% | 11 | 85% | 9 | 82% |
| In the past 3 months | 1 | 8% | 8 | 15% | 7 | 16% | 6 | 12% | 1 | 8% | 2 | 18% |
| In the past 4–12 months | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 2% | 1 | 8% | 0 | 0% |
| Chlamydia diagnosise | ||||||||||||
| No | 23 | 85% | 65 | 93% | 69 | 95% | 86 | 100% | 13 | 93% | 19 | 83% |
| Yes | 4 | 15% | 6 | 7% | 4 | 5% | 0 | 0% | 1 | 7% | 4 | 17% |
| LGV diagnosise | ||||||||||||
| No | 24 | 89% | 69 | 99% | 73 | 100% | 86 | 100% | 14 | 100% | 22 | 96% |
| Yes | 3 | 11% | 1 | 1% | 0 | 0% | 0 | 0% | 0 | 0% | 1 | 4% |
| Gonorrhea diagnosise | ||||||||||||
| No | 22 | 81% | 64 | 91% | 67 | 92% | 84 | 98% | 13 | 93% | 19 | 83% |
| Yes | 5 | 19% | 6 | 9% | 6 | 8% | 2 | 2% | 1 | 7% | 4 | 17% |
| Herpes simplex diagnosise | ||||||||||||
| No | 21 | 78% | 70 | 100% | 72 | 99% | 84 | 98% | 14 | 100% | 18 | 78% |
| Yes | 6 | 22% | 0 | 0% | 1 | 1% | 2 | 2% | 0 | 0% | 5 | 22% |
| Notified for syphilis | ||||||||||||
| No | 23 | 85% | 58 | 83% | 62 | 85% | 86 | 100% | 14 | 100% | 19 | 83% |
| Yes | 4 | 15% | 12 | 17% | 11 | 15% | 0 | 0% | 0 | 0% | 4 | 17% |
| RPR | ||||||||||||
| Median [IQR] | NA | NA | 2 | [0–8] | 16 | [16–32] | 8 | [4–32] | 6 | [0–8] | 0 | [0–1] |
| Negative | 27 | 100% | 21 | 30% | 0 | 0% | 10 | 12% | 4 | 29% | 17 | 74% |
| Low (1:1–1:4) | NA | NA | 24 | 34% | 4 | 5% | 13 | 15% | 3 | 21% | 5 | 22% |
| Middle (1:8–1:16) | NA | NA | 15 | 21% | 38 | 52% | 39 | 45% | 7 | 50% | 1 | 4% |
| High (1:32–1:128) | NA | NA | 10 | 14% | 31 | 42% | 24 | 28% | 0 | 0% | 0 | 0% |
Abbreviations: cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; LGV, lymphogranuloma venereum; NA, not applicable; no., number; PrEP, pre-exposure prophylaxis; RPR, rapid plasma reagin.
Data missing for: country of origin (n = 1), education level (n = 29), number of sexual partners (n = 6), ART use (n = 4), and most recent CD4 count (n = 26).
Unless otherwise stated.
In the 6 months before the consultation.
In patients with HIV.
In HIV negative men only.
At current visit.